Navigation Links
Genes Play Part in Prostate Cancer Among Races
Date:5/15/2008

Whites at higher risk than Hispanics, but genetics determines who gets it

THURSDAY, May 15 (HealthDay News) -- Genetic differences may explain why white men have a higher prostate cancer risk than Hispanic men, information which may help doctors identify men who are more likely to develop the disease, U.S. researchers say.

They collected blood samples from 932 white men and 414 Hispanic men from south Texas and looked for mutations from the nuclear vitamin D receptor (CDX2 and FokI), which modulates the actions of vitamin D, and from 5-reductase type II (V89L & A49T), which converts testosterone to dihydrotestosterone, a more potent form of the male hormone.

Among non-Hispanic white men with V89L, FokI was associated with a more than a 50 percent increased risk of prostate cancer. This effect was not seen in Hispanic men. Among Hispanic white men, a combination of CDX2 and V89L was associated with a more than threefold increased risk of prostate cancer. This link was not seen in white men.

The findings, published in the May 15 issue of Clinical Cancer Research, provide new information about genetic risks and racial differences, but need to be confirmed in larger studies.

"Prostate cancer is not likely caused by a few genes, but by multiple genes from different pathways. This study illustrates the importance of examining multiple genes to understand genetic risks for prostate cancer and differences seen by ethnicity," study author Kathleen Torkko, an instructor in the department of pathology at the University of Colorado, Denver, said in a prepared statement.

"Going forward, we need not only a better understanding of genetics but a better understanding of race and ethnicity. Studying disease by race is a complex issue, and the public needs to understand that we are trying to raise biological, rather than social, questions," Torkko said.

She said the goal of this research is to find ways to improve management and treatment of prostate cancer. Currently, the most common method for assessing prostate cancer risk is the prostate specific antigen (PSA) test. But the test can identify tumors that may not be a threat, while missing other tumors.

"Men typically have this test after they turn 50 years old, and it can spot a tumor that may not cause a problem in a man's lifetime if left untreated. It could be more likely that a man will die from heart disease or some other ailment before his prostate cancer would kill him," Torkko said.

"At this point, it is not possible to accurately tell which tumors will be the more aggressive ones with our current screening tests. This means that we may be screening and treating some men unnecessarily," she noted.

More information

The National Cancer Institute has more about prostate cancer screening.



-- Robert Preidt



SOURCE: American Association for Cancer Research, news release, May 15, 2008


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Connecting cancer genes
2. Cardiogenesis Reports First Quarter 2008 Results
3. Effect of mutant p53 stability on tumorigenesis and drug design
4. Hoffa, Cherry to Speak at Community Rally Supporting Genesys Nurses
5. Bread mold may hold secret to eliminating disease-causing genes
6. Unraveling the Link Between Genes and Environment
7. Cardiogenesis Corporation to Report 2008 First Quarter Results on May 15th
8. Genes Linked to Osteoporosis Identified
9. Environment key early: Genes role expands in alcohol dependence
10. A stem cell type supposed to be crucial for angiogenesis and cancer growth does not exist?
11. Breast cancer risk amplified by additional genes in combo with BRCA mutation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... MD (PRWEB) , ... March 29, 2017 , ... ... is proud to announce the finalization of the company’s executive management team with prominent ... and leading operations is Curio Wellness’ Chief Operating Officer, Ted Dumbauld , who ...
(Date:3/29/2017)... Linda, Ca (PRWEB) , ... March 29, 2017 , ... ... of a growing number of cancers and is touted to be the next revolution ... treatment, thus far, has been in the form of immune checkpoint inhibitors such as ...
(Date:3/29/2017)... ... 29, 2017 , ... The Wharton School of the University of Pennsylvania is ... made a $10 million gift to establish the Ken Moelis and Julie Taffet ... to a Wharton MBA for highly-qualified Penn undergraduates whose academic and career interests expand ...
(Date:3/28/2017)... CA (PRWEB) , ... March 28, 2017 , ... Tuesday, ... asking the American public to take the Diabetes Risk Test to find out if ... the Los Angeles World Airports will light up the evening sky by programming the ...
(Date:3/28/2017)... ... March 28, 2017 , ... Resoundant, ... be invited to the Siemens Healthineers annual customer education symposium, a world-class learning ... take place from March 27 - 31, 2017 at the Atlanta Marriott Marquis ...
Breaking Medicine News(10 mins):
(Date:3/29/2017)... Research and Markets has announced the addition of the ... to their offering. ... The ablation device global market is expected to grow at ... Ablation is the minimally invasive therapeutic tissue excision procedure ... tissue removal, to the removal of abnormally conducting cardiac tissue in ...
(Date:3/29/2017)...   Royal Philips (NYSE: PHG, AEX: ... PathAI, a company that develops artificial intelligence technology ... develop solutions that improve the precision and accuracy ... The partnership aims to build deep learning applications ... intelligence to be applied to massive pathology data ...
(Date:3/29/2017)... , March 29, 2017 On March 28, the U.S. ... adult patients with relapsing forms of multiple sclerosis (MS) ... first drug approved by the FDA for PPMS. Ocrevus ... professional.  "Multiple sclerosis can have a ... Dunn , M.D., director of the Division of Neurology ...
Breaking Medicine Technology: